User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -5.00 -2.9% 167.50 165.00 170.00 172.50 167.50 172.50 215,898 16:09:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 300

Amryt Pharma Share Discussion Threads

Showing 6451 to 6475 of 6650 messages
Chat Pages: 266  265  264  263  262  261  260  259  258  257  256  255  Older
DateSubjectAuthorDiscuss
06/3/2021
08:17
Morning all! Can anyone remember what the original share price was? I mean for the previous "entity"...when it was listed...Fastnet?? ....getting old....😔 8532;
thecynical1
05/3/2021
22:20
Because there aren't any good alternatives.
delta0091
05/3/2021
22:17
FDA Approval Does Not Mean the Drug or Vaccine Works Well However, a major caveat is that just because a drug or vaccine is deemed a success by receiving FDA approval does not mean it works particularly well. Why would the FDA approve something like that? Because there aren't any good alternatives. For instance, neither the antiviral drug Tamiflu nor the seasonal flu vaccine are particularly impressive. But, there's nothing better available. hxxps://www.acsh.org/news/2020/06/11/clinical-trial-success-rates-phase-and-therapeutic-area-14845
delta0091
05/3/2021
15:08
I got the impression from the presentation that management were in talks about distribution of new products. I would not be surprised if this was relatively soon. They stated that their strong preference was rights for North America and EMEA, but if only EMEA was available they would be likely to go for it. That could be catalyst for next move, but November is not that far away. Fingers crossed!
sidam
05/3/2021
14:35
whatno, I accept FDA approval is odds on, but nothing is guaranteed. That is why the AMYT share price is not yet discounting that FDA approval being given! Yes, bazworth, why raise that 40m? Surely it was to increase the cash coffers ready for an acquisition? Don't forget investors who took part in the placing got relatively cheap shares for that 40m they stumped up. Perhaps it was just a chance for some II's to build a significant stake in AMYT without pushing up the price by buying in the market? Just as rational and logical argument as the acquisition one.
papillon
05/3/2021
13:16
Papillon - I don't think there is much doubt that it will get approved. The Ease trial was very well designed so the FDA is very unlikely to reject on an efficacy/safety basis. The factor that most often causes an unexpected CRL is manufacturing. The FDA will normally perform site inspections at the plant where the drug is produced. During the pandemic, FDA has instead submitted written questions to the manufacturers about various aspects of their processes - it's like taking an exam - get a question wrong and you fail, badly! NDAs that are rejected the first time around for this reason normally make it through on the second attempt.
whatno
05/3/2021
12:43
Mind you, there must have been something that floated the boat of those who fairly recently stumped up $40m!!
bazworth
05/3/2021
12:16
Let's face facts. The AMYT share price won't jump up until we get FDA approval for the EB treatment and the company can then flog off the fast track approval for mega bucks (around US$100m?). When that FDA approval is received is anybodies guess. Hopefully it will be soon. Of course there is always the possibility it will not be given. Dread the thought!
papillon
04/3/2021
21:18
Let's hope that the Mail tips AMYT over the weekend. They usually do after a good results RNS. AMYT is one of their favourites for tipping.
papillon
04/3/2021
19:51
Sh*t on Nasdaq tonight. Not doing AMYT any favours
papillon
04/3/2021
16:00
AH yes, but securing approval from the FDA the first time around is not a trivial exercise as anyone that trades PDUFA dates will know. I draw your attention to the share price of CorMedix - CRMD (NASDAQ) on Monday as an example of a company that received an FDA Complete Response Letter (CRL) vs the share price of KemPharm - KMPH (NASDAQ) that received FDA marketing approval yesterday. PDUFA is an extremely risky time for investors and shares prices are absolutely devastated by a CRL. Anyone who does not understand this should not be invested in pharma. In Amryt's case, it is true that because they have existing revenue streams, a CRL would not break the company but it would take at least 9 months to a year to secure marketing approval second time around. The CVR would have expired by then.
whatno
04/3/2021
15:02
In the presentation they said a decision was expected in November from the FDA and if positive launch would follow, but this was not included in guidance for this year. A decision in Europe was expected in early 2022. So initial CVRs should have value if the decision is positive and not delayed.
sidam
04/3/2021
14:10
I understood that approval was expected around September?
bazworth
04/3/2021
13:37
All good news but no real surprises. I would expect the next big catalyst for the share price will be acceptance of the NDA by the FDA, judging from recent FDA filing acceptances. Given that Amryt state they will file in Q1 and the FDA confirms within a month, we should be looking at some time in April.. In other words, pretty soon! As a CVR holder, I have fingers crossed that Amryt will not get the knockback from the FDA either on filing or approval. If they do, the delay will probably mean the FDA CVRs will expire, by the middle of next year, I believe). I would be gutted after holding for so long!
whatno
04/3/2021
13:34
Very happy to be a holder
moorsie2
04/3/2021
13:12
I’m happy - all going very well by the look of it and more growth to come. The share price may give us all a good ‘whoooooshR17; at some point. Not a problem to hold and be patient!!
bazworth
04/3/2021
12:45
Call at 1.30 if anyone wants to listen in
waterloo01
04/3/2021
12:39
cash flow is impressive .. $48m
delta0091
04/3/2021
12:24
4p. 🤣 Let's see what happens when Nasdaq opens.
papillon
04/3/2021
12:21
And so the share price moves 1p.
babbler
04/3/2021
12:05
Joe Wiley, CEO of Amryt Pharma, commented: "I am very pleased with today's strong results for 2020 which demonstrate the very positive performance and growth that our commercial products are delivering, coupled with the significant progress we are achieving in our exciting development pipeline of new therapeutic drug candidates. Our business continues to perform and grow strongly. In particular, our revenue growth exceeded expectations and the fact that we turned EBITDA profitable has translated into a significant increase in our cash balances. Given the strong performance of our business in 2020, we are now issuing revenue guidance for FY 2021 of $200-$205 million which demonstrates our confidence in Amryt's prospects.
waterloo01
04/3/2021
07:06
Results mid-day I believe!
bazworth
04/3/2021
06:58
Let's hope it's a good one ab321.
papillon
04/3/2021
06:47
Interesting day ahead!
alphabravo321
02/3/2021
23:16
Could be a bullish triangle formation on the AMYT chart with a target price 0f 280p, or it could be I've overdosed on Prozac! 🤣. Final Results on Thursday and surprisingly big volume on Nasdaq today. free stock charts from uk.advfn.com
papillon
Chat Pages: 266  265  264  263  262  261  260  259  258  257  256  255  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210509 07:28:56